Neuroendocrine tumors (NETs) are tumors that arise from cells of the endocrine and nervous systems. More than ten years of published clinical data and personal
experience using PRRT-based targeted therapy of neuroendocrine tumors
supports the effectiveness of this novel treatment approach and the
ability to minimize and manage potential toxic side effects.
A
comprehensive review of somatostatin analog peptide receptor
radionuclide therapy (PRRT) is published in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.
Carcinoid Tumors
Carcinoid tumors is a benign tumor that results in carcinoid syndrome. Only 8 to 10% of all carcinoid tumors are associated with the carcinoid syndrome.
Advertisement
‘Peptide receptor radionuclide therapy (PRRT) has revolutionized the management of neuroendocrine tumors, improving response rates and progression-free survival.’
Tweet it Now
In the article "Myelotoxicity of Peptide Receptor Radionuclide Therapy of Neuendocrine Tumors: A Decade od Experience," Murali Kesavan and J. Harvey Turner, The University of Western Australia (Crawley, Australia), state that PRRT has revolutionized the management of patients with neuroendocrine tumors, improving tumor response rates and patients' progression-free survival. However, the associated toxicity to blood cells - with the potential to cause thrombocytopenia and neutropenia and, in the long term, myelodysplastic syndrome and acute leukemia - remains a risk and has limited the use of PRRT.
The researchers suggest that PRRT should more readily be considered a
first-line agent in appropriate patients. Steps can be taken to
minimize the risk of significant long-term effects, such as appropriate
timing of therapy, patient selection criteria, dose optimization, and
adequate monitoring.
![First Whole Exome Sequence of Small Intestine Neuroendocrine Tumors Completed by Mayo Clinic]( "First Whole Exome Sequence of Small Intestine Neuroendocrine Tumors Completed by Mayo Clinic")
The world's first whole exome sequence of small intestine neuroendocrine tumors has been completed by researchers at Mayo Clinic.
"This is an important discussion of the efficacy and toxicity issues relating to the use of PRRT, as the therapy becomes more widely available for the treatment of gastroenteropancreatic neuroendocrine tumors with radiolabeled somatostatin analogs," says Co-Editor-in-Chief Donald J. Buchsbaum, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham.
Source: Eurekalert
First Whole Exome Sequence of Small Intestine Neuroendocrine Tumors Completed by Mayo Clinic
The world's first whole exome sequence of small intestine neuroendocrine tumors has been completed by researchers at Mayo Clinic.
Advertisement
"This is an important discussion of the efficacy and toxicity issues relating to the use of PRRT, as the therapy becomes more widely available for the treatment of gastroenteropancreatic neuroendocrine tumors with radiolabeled somatostatin analogs," says Co-Editor-in-Chief Donald J. Buchsbaum, Department of Radiation Oncology, Division of Radiation Biology, University of Alabama at Birmingham.
Source: Eurekalert
Efficiency of Radionuclide Therapy for Neuroendocrine Tumors
A peptide based radio-labeled therapy is effective in decreasing tumor size and reducing the severity of side effects that accompany a cancer diagnosis, finds research.
Advertisement
 Everolimus Benefits Patients With Neuroendocrine TumorsEverolimus, improves progression-free survival for patients with advanced neuroendocrine tumors and a history of carcinoid syndrome. | Advertisement
|
Advertisement